BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of ($0.32), $0.14 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $400 million versus the consensus estimate of $389.69 million.

• 2019 Full-Year Financial Guidance unchanged

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.